New data show that dual-target CAR T therapy induces durable remissions in children with high-risk B-cell leukaemia, offering ...

Preexisting autoimmune diseases are tied to shorter hospital stays and less toxicity risk in patients receiving chimeric ...

CAR-T therapy was originally developed for leukemias and lymphomas, and the breakthrough treatment is now also being used for ...

The U.S. Food and Drug Administration (FDA) has granted a regenerative medicine advanced therapy designation to MB-105, a CD5 ...

The autologous CAR-T cell therapy MB-105 has received regenerative medicine advanced therapy (RMAT) designation from the FDA ...

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of ...

Only a few dozen patients with lupus have been treated with CAR-T-cell therapy — but in a small German study, all five ...

A new type of cancer cell that "warrants urgent investigation" has been discovered in childhood leukemia and could impact ...

On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

A new systematic review shows CAR T-cell therapy delivers high remission rates, reduced disease activity, and low toxicity in ...

The treatment landscape for systemic lupus erythematosus (SLE) has shifted greatly in recent years, driven by the emergence ...